What is the significance of the Alberta Stroke Program Early CT Score (ASPECTS) in stroke patients, when is it used, and how does it compare to the National Institutes of Health Stroke Scale (NIHSS) and other scoring systems?

ASPECTS: A Critical Imaging Tool for Stroke Treatment Decisions

ASPECTS (Alberta Stroke Program Early CT Score) is a 10-point quantitative scoring system that assesses the extent of early ischemic changes in the middle cerebral artery territory on non-contrast CT, primarily used to predict functional outcomes and guide treatment decisions for acute ischemic stroke, particularly for endovascular therapy eligibility. 1, 2

What ASPECTS Measures and How It Works

ASPECTS divides the MCA territory into 10 standardized regions of interest. Each region showing early ischemic changes (hypoattenuation, loss of gray-white differentiation, or focal swelling) receives a 1-point deduction from the baseline score of 10. A score of 10 indicates no visible ischemic changes, while lower scores indicate more extensive early infarction. 3, 2

The 10 regions assessed include:

• Deep structures: Caudate, lentiform nucleus, internal capsule, insular ribbon
• Cortical regions: M1-M6 territories (anterior, lateral, and posterior MCA cortical regions)

Clinical Significance and Predictive Value

Outcome Prediction

ASPECTS strongly predicts both functional outcome and hemorrhagic transformation risk. Patients with ASPECTS ≤7 show a sharp increase in dependence and death rates. 3 The score inversely correlates with stroke severity on NIHSS (r=-0.56, p<0.001) and directly predicts 3-month functional independence. 2

For predicting functional outcome, ASPECTS demonstrates sensitivity of 0.78 and specificity of 0.96; for symptomatic intracerebral hemorrhage, sensitivity is 0.90 and specificity is 0.62. 2

Treatment Decision-Making

The lower the ASPECTS, the higher the risk of intracranial hemorrhage and poor functional outcome despite treatment with alteplase and/or endovascular therapy. 4 However, this doesn't mean treatment should be withheld in all low-ASPECTS patients—the decision requires nuanced clinical judgment.

When ASPECTS Is Used

Endovascular Therapy Selection (Primary Use)

ASPECTS ≥6 is the established threshold for endovascular therapy eligibility in most clinical scenarios. 1, 5

Within 0-6 hours from symptom onset:

• ASPECTS ≥6 is recommended for EVT eligibility (Level A evidence) 1, 5
• Patients should have proximal anterior circulation occlusion confirmed on CTA/MRA
• Combined with moderate-to-good collaterals on CTA or CT perfusion mismatch 1

Within 6-24 hours (extended window):

• ASPECTS ≥6 remains the recommended threshold 1, 6
• More stringent selection criteria apply, often requiring additional perfusion imaging
• Used in conjunction with clinical-imaging mismatch assessment 4

For ASPECTS <6:

• Treatment decisions should be individualized based on clinical judgment 1
• Evidence from MR CLEAN trial showed treatment effect favored intervention across all ASPECTS subgroups, though the benefit in ASPECTS 0-4 was uncertain (OR 1.09,95% CI 0.14-8.46) 5
• Further randomized trials are warranted for this population 5

Thrombolysis Decisions

While ASPECTS was primarily developed for EVT selection, it also informs IV tPA decisions. When baseline CT shows ASPECTS <6, the decision to treat with tPA should be based on treating physician's clinical judgment. 1

ASPECTS vs. NIHSS: Different Tools, Different Purposes

Fundamental Differences

NIHSS and ASPECTS serve complementary but distinct roles—they are not competing scoring systems.

NIHSS (National Institutes of Health Stroke Scale):

• Clinical assessment tool measuring neurological deficit severity 7
• 11-15 items examining consciousness, vision, motor function, sensation, language, and attention
• Administered in 5-10 minutes by any trained clinician
• Score range: 0-42 (higher = more severe)
• Primary uses: Stratify stroke severity, guide acute treatment decisions, predict outcomes 7
• Timing: Performed at presentation, 24 hours, and discharge 7
• Score >16 predicts high probability of death/severe disability; <6 predicts good recovery 7

ASPECTS:

• Imaging-based assessment of early ischemic changes 3, 2
• Requires CT scan interpretation (though can be automated)
• Score range: 0-10 (higher = less ischemic change)
• Primary uses: Estimate ischemic core size, predict hemorrhagic transformation risk, guide EVT eligibility 4, 1
• Timing: Baseline imaging before treatment decisions

When Each Is Used

NIHSS is mandatory for all acute stroke patients to assess severity and guide immediate treatment decisions (IV tPA eligibility, EVT consideration). 7, 8

ASPECTS is specifically used when:

• Considering endovascular therapy for large vessel occlusion 1, 5
• Assessing hemorrhagic transformation risk
• Evaluating patients in extended time windows (6-24 hours) 1, 9
• Quantifying early ischemic changes more systematically than the outdated "1/3 MCA rule" 3

The NIHSS-ASPECTS Mismatch Concept

Recent research suggests that mismatch between NIHSS severity and ASPECTS findings may help refine treatment decisions. Patients with high NIHSS scores but preserved ASPECTS (NIHSS-ASPECTS mismatch positive) showed better functional outcomes with IVT treatment at 3 months (p=0.005) and 1 year (p=0.001), with higher rates of favorable mRS 0-2 outcomes. 10 This mismatch indicates clinical severity disproportionate to visible ischemic changes, suggesting salvageable tissue.

Comparison with Other Scoring Systems

ASPECTS vs. CT Perfusion (CTP)

• ASPECTS advantages: Simpler, faster, whole-brain coverage, no post-processing required, robust against motion, widely available 4
• CTP limitations: Technical failures in up to 30%, vendor variability, limited brain coverage (8-16 cm slab), requires post-processing 4
• Key point: MR CLEAN subgroup analysis showed CTP did not add value to treatment decision-making 4

ASPECTS vs. DWI-MRI

• DWI-MRI is more sensitive for detecting acute ischemia, especially in posterior fossa 4
• ASPECTS is faster and more practical in hyperacute settings
• MRI not required before basilar artery thrombectomy, though helpful when available 9

ASPECTS vs. Modified Rankin Scale (mRS)

• mRS measures functional outcome (0-6 scale), not acute stroke severity
• Used as endpoint, not selection criterion
• ASPECTS predicts mRS outcomes 2, 11

Critical Caveats and Limitations

Interobserver Reliability

Agreement between observers is substantial to excellent for total ASPECTS (κ=0.67 for kappa studies, ICC=0.84 for ICC studies), but varies significantly by brain region. 12

Highest agreement regions: Caudate nucleus (κ=0.68, ICC=0.84) Lowest agreement regions: M2, M4, and internal capsule (κ=0.45-0.47, ICC=0.54-0.55) 12

Training is essential—ASPECTS assessment requires specific education and practice. 13 Agreement improves when observers are unblinded to clinical scenario. 12

Common Pitfalls

1. Isolated cortical swelling without parenchymal hypoattenuation should not be scored as early ischemic change 13

2. ASPECTS only applies to anterior circulation (MCA territory) strokes—posterior circulation uses PC-ASPECTS with different methodology 9

3. Serial ASPECTS (baseline to 24 hours) provides better prognostic information than baseline alone. Dramatic infarct progression (≥6 point decrease) occurs in 28% of patients with initially high ASPECTS (8-10) and predicts worse outcomes. 11

4. Predictors of dramatic progression: Hyperglycemia, hypertension, and failure to achieve reperfusion 11

5. ASPECTS can be applied to different CT axial baselines due to normal anatomic variations, making it robust across imaging protocols 3

When ASPECTS May Be Insufficient

For basilar artery occlusion, PC-ASPECTS ≥6 is recommended rather than standard ASPECTS. 9 Age limits should not represent contraindication for thrombectomy regardless of ASPECTS. 6

Practical Algorithm for Use

Step 1: Obtain non-contrast CT immediately upon stroke presentation

Step 2: Assess ASPECTS systematically across all 10 MCA regions

Step 3: Apply treatment thresholds:

• ASPECTS 8-10: Strong candidate for all reperfusion therapies
• ASPECTS 6-7: Eligible for EVT within guidelines; consider clinical factors
• ASPECTS <6: Individualized decision; uncertain benefit but not absolute contraindication; consider time window, NIHSS severity, collateral status

Step 4: Integrate with other factors:

• Time from onset (0-6h vs 6-24h)
• NIHSS score (≥6 for EVT consideration)
• Vessel imaging (confirm LVO)
• Collateral assessment
• Patient age and baseline function

Step 5: For extended window (6-24h), consider additional perfusion imaging if available, though ASPECTS alone may suffice for centers without multimodal imaging 14

4, 1, 9, 4, 5, 10, 13, 3, 2, 11, 12, 14